NCT06697613 is a clinical trial of Hyperthermic intraperitoneal chemotherapy in Ovarian Cancer, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

Who is sponsoring NCT06697613?

NCT06697613 is sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

What drugs are being tested in NCT06697613?

Interventions in NCT06697613: Hyperthermic intraperitoneal chemotherapy.

What condition does NCT06697613 study?

NCT06697613 studies Ovarian Cancer, AKI - Acute Kidney Injury.

Is NCT06697613 still recruiting?

NCT06697613 is currently completed. Last updated 20 November 2024.

Last reviewed 2024-11-20 · How we verify

NCT06697613

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Development and Validation of a Prediction Model for AKI Following Cisplatin-Based HIPEC in Patients With Ovarian Cancer

Completed Last updated 20 November 2024

What this trial tests

trial testing Hyperthermic intraperitoneal chemotherapy in Ovarian Cancer in 150 participants. Completed in 31 August 2024.

Timeline

1 January 2016

Primary endpoint
30 June 2024

31 August 2024

Quick facts

Lead sponsor	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	150
Start date	1 January 2016
Primary completion	30 June 2024
Estimated completion	31 August 2024
Sites	1 location across China

Drugs / interventions tested

Hyperthermic intraperitoneal chemotherapy — full drug profile →

Conditions studied

Ovarian Cancer — all drugs for Ovarian Cancer →
AKI - Acute Kidney Injury — all drugs for AKI - Acute Kidney Injury →

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Who can join

Adults 18 to 75, female only, with Ovarian Cancer or AKI - Acute Kidney Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Ovarian cancer is the most lethal malignant tumor of the female reproductive system. Cytoreduction surgery(CRS) combined with chemotherapy is the primary method for treating ovarian cancer, and complete tumor resection is an important means to improve prognosis. It has been demonstrated that the use of cisplatin for hyperthermic intraperitoneal chemotherapy (HIPEC) following CRS can significantly improve the prognosis of some patients with ovarian cancer. However, HIPEC with cisplatin can lead to acute kidney injury (AKI), a serious complication that can seriously affect the patient's short- and long-term prognosis. NCCN guidelines recommend the use of sodium thiosulfate in all patients receiving HIPEC. This study intends to retrospectively collect clinical characteristics of patients to establish a prediction model for kidney injury, with a view to screening those at high risk of kidney injury for use of sodium thiosulfate for nephrotoxicity rescue in cisplatin HIPEC.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Hyperthermic intraperitoneal chemotherapy

Trials testing the same drug.

NCT06544460 — Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients · Phase 2 · not yet recruiting

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University trials

Trials by the same sponsor.

NCT07168083 — Efficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy Progression · not yet recruiting
NCT07413497 — A Prospective Observational Clinical Study on Exploring the Value of Surgical Excision Combined With 32P Application in · not yet recruiting
NCT07461077 — Noninvasive Implantation Potential vs Morphology-Based Selection in IVF Single Blastocyst Transfer · NA · not yet recruiting
NCT07533526 — Effects of Instrument-Assisted Constant-Speed Injection Versus Manual Injection on Pain From Large-Volume Subcutaneous I · NA · not yet recruiting
NCT07408648 — A Clinical Study on the Efficacy and Safety of Hetrombopag in the Treatment of Thrombocytopenia Induced by Gynecological · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06697613 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Last refreshed: 20 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06697613.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing